AstraZeneca Pharma India Ltd. — Board/Management Information 2023

Nov 9, 2023

==> picture [512 x 78] intentionally omitted <==

November 9, 2023

The Manager – Listing BSE Limited , 1[st] Floor, New Trading Ring Rotunda Buiding, P J Towers, Dalal Street, Fort, Mumbai - 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai - 400051

Dear Sir(s),

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure - - Requirements) Regulations, 2015 Appointment of Additional Director (Non Executive)

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Ms. Hooi-Bien Chuah (DIN: 10381891), as an Additional Director (Non-Executive) of the Company with effect from November 9, 2023.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 attached herewith as Annexure – A.

We request you to please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited

MANAS Digitally signed by MANASA RAMA A RAMA Date: 2023.11.09 16:31:19 +05'30' Manasa. R Company Secretary

==> picture [453 x 64] intentionally omitted <==

==> picture [512 x 78] intentionally omitted <==

Annexure - A Appointment of Ms. Hooi-Bien Chuah (DIN: 10381891) as an Additional Director (NonExecutive) on the Board of Directors of the Company

Sl. No		Particulars	Details
1		Reason for change viz. appointment, ~~resignation,~~ ~~removal, death or otherwise~~;	Appointment of Ms. Hooi-Bien Chuah (DIN: 10381891) as an Additional Director (Non-Executive).
2		Date of appointment and term of appointment	Effective : November 9, 2023 Term of appointment – Not Applicable
3		Brief Profile	Ms. Hooi Bien is Asia Area Legal Director for AstraZeneca since April 2021. She has over two decades of legal experience spanning across pharmaceutical, consumer health, technology, and oil & gas industries. Prior to AstraZeneca, she was with Lazada, an e- commerce marketplace platform and logistics company under the Alibaba Group, as SVP Head of Legal (Malaysia) and Litigation Centre of Excellence lead (Southeast Asia). Hooi Bien was also the Legal Director and Ethics & Compliance Officer for GSK Malaysia & Brunei, and had served Shell Malaysia and UCB Asia Pacific in legal and company secretary roles, after starting out her career in private practice with Messrs. K.B. Chua & Co in 1998. Hooi Bien holds an MBA from the University of Strathclyde and an LLB (Honours) from the University of Leicester, and was called to the English Bar and Malaysian Bar in 1997 and 1998 respectively. She also held a Leading Professional in Ethics & Compliance certification. In recognition of various achievements, Hooi Bien and her teams had received multiple Asian Legal Business awards, including In-House Lawyer of the Year 2016 (Southeast Asia), Pharmaceutical & Healthcare Team of the Year 2022 (Southeast Asia), Technology, Media & Telecommunications Team of the Year 2021 (Malaysia) and Innovative Team of the Year 2020 (Malaysia).
4		Disclosure of relationships between directors	None

==> picture [453 x 64] intentionally omitted <==